Company: BLTE
Filing Date: 2025-01-27
Form Type: F-3ASR
Source: 0001104659-25-006317
Chunk: 3

Company: BELITE BIO, INC
Filing Date: 2025-01-27
Form: F-3ASR
Chunk 3
---
 | ​ |
| PLAN OF DISTRIBUTION                                      | ​ | ​ | ​    | ​ | 48 | ​ | ​ |
| WHERE YOU CAN FIND MORE INFORMATION                       | ​ | ​ | ​    | ​ | 50 | ​ | ​ |
| INCORPORATION BY REFERENCE                                | ​ | ​ | ​    | ​ | 51 | ​ | ​ |
| ENFORCEABILITY OF CIVIL LIABILITIES                       | ​ | ​ | ​    | ​ | 52 | ​ | ​ |
| LEGAL MATTERS                                             | ​ | ​ | ​    | ​ | 54 | ​ | ​ |
| EXPERTS                                                   | ​ | ​ | ​    | ​ | 55 | ​ | ​ |

i

TABLE OF CONTENTS

### ABOUT THIS PROSPECTUS
This prospectus is part of an “automatic shelf” registration statement on Form F-3 that we filed with the Securities and Exchange Commission, or SEC, as a “well-known seasoned issuer” as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act, utilizing a “shelf” registration process. Under this shelf registration process, we or selling shareholders may offer our ordinary shares, including ADSs representing our ordinary shares, preferred shares, warrants, overallotment purchase rights, subscription rights, units, capital notes and/or debt securities either individually or in combination with other securities, in one or more offerings. There is no limit on the aggregate amount of the securities that we or selling shareholders may offer pursuant to the registration statement of which this prospectus is a part. This prospectus provides you with a general description of the securities we or selling shareholders may offer.

This prospectus only provides you with a general description of the securities that we may offer. Each time we sell our securities, we will provide a prospectus supplement containing specific information about the offering, if required. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. Any such prospectus supplement and any related free writing prospectuses to be provided to you may include a discussion of any risk factors or other special considerations or information that apply to that offering. The prospectus supplement and any related free writing prospectuses may also add, update or change the information in this prospectus. Before purchasing any of our securities, you should carefully read the registration statement, including exhibits to the registration statement, this prospectus and any prospectus supplement together with additional information